Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 11;8(15):25806-25813.
doi: 10.18632/oncotarget.15709.

Repressing CD147 is a novel therapeutic strategy for malignant melanoma

Xing Hu  1   2 , Juan Su  1   2 , Youyou Zhou  2 , Xiaoyun Xie  1   2 , Cong Peng  1   2 , Zhimin Yuan  3 , Xiang Chen  1   2
Affiliations
Review

Repressing CD147 is a novel therapeutic strategy for malignant melanoma

Xing Hu et al. Oncotarget. .

Abstract

CD147/basigin, a transmembrane protein, is a member of the immunoglobulin super family. Accumulating evidence has revealed the role of CD147 in the development and progression of various cancers, including malignant melanoma (MM). MM is a malignancy of pigment-producing cells that causes the greatest number of skin cancer-related deaths worldwide. CD147 is overexpressed in MM and plays an important role in cell viability, apoptosis, proliferation, invasion, and metastasis, probably by mediating vascular endothelial growth factor (VEGF) production, glycolysis, and multi-drug resistance (MDR). As a matrix metalloproteinase (MMP) inducer, CD147 could also promote surrounding fibroblasts to secrete abundant MMPs to further stimulate tumor cell invasion. Targeting CD147 has been shown to suppress MM in vitro and in vivo, highlighting the therapeutic potential of CD147 silencing in MM treatment. In this review article, we discuss CD147 and its biological roles, regulatory mechanisms, and potential application as a molecular target for MM.

Keywords: CD147; MMPs; cell proliferation; cyclophilin A; melanoma.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

There is no conflict of interest.

Figures

Figure 1
Figure 1. Molecular pathways of CD147 in malignant melanoma
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden Globocan 2000. Int J Cancer. 2001;94:153–6. - PubMed
    1. Cockburn MG, Zadnick J, Deapen D. Developing epidemic of melanoma in the Hispanic population of California. Cancer. 2006;106:1162–8. doi: 10.1002/cncr.21654. - DOI - PubMed
    1. Linos E, Swetter SM, Cockburn MG, Colditz GA, Clarke CA. Increasing burden of melanoma in the United States. J Invest Dermatol. 2009;129:1666–74. doi: 10.1038/jid.2008.423. - DOI - PMC - PubMed
    1. Rigel DS, Russak J, Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin. 2010;60:301–16. doi: 10.3322/caac.20074. - DOI - PubMed
    1. Beddingfield FC., 3rd The melanoma epidemic: res ipsa loquitur. Oncologist. 2003;8:459–65. - PubMed

MeSH terms